期刊文献+

不同感染状态下梅毒患者血清白介素2、10和12检测结果分析 被引量:9

下载PDF
导出
摘要 梅毒是由梅素螺旋体(TP)引起的一种慢性性传播性疾病,可以引起全身各组织器官的损害,临床表现复杂多样。部分患者在出国、婚检、献血及手术等情况下意外发现,具体感染日期不明,且无临床表现,在排除神经梅毒后,称之为潜伏梅毒;另外部分患者经积极正规治疗,快速血浆反应素环状卡片试验(RPR)滴度在早期梅毒半年、晚期梅毒1年以上不能下降或阴转,称之为血清固定:而大部分患者经治疗后RPR能够下降直至阴转。上述3类患者均无临床症状,但处于不同的感染状况。
出处 《临床皮肤科杂志》 CAS CSCD 北大核心 2012年第6期351-353,共3页 Journal of Clinical Dermatology
基金 南通市社会发展科技计划基金(s2009046)资助项目
  • 相关文献

参考文献9

二级参考文献59

  • 1杨日东,蔡川川,田广南,黎小东,张文君,陈展琳,梁慕兰.血清固定梅毒患者细胞免疫研究[J].中国实验诊断学,2004,8(5):477-479. 被引量:21
  • 2周平玉,熊思东,阎春林,徐金华,廖康煌.梅毒患者皮损中Th1/Th2细胞因子表达与RPR试验阴转的关系[J].中华皮肤科杂志,2004,37(12):712-714. 被引量:7
  • 3杨文林,杨健,黄新宇.近10年梅毒血清固定患者临床分析[J].临床皮肤科杂志,2005,34(11):719-721. 被引量:89
  • 4[1]Pope V, Larsen SA, Rice RJ, et al. Flow cytometric analysis of peripheral blood lymphocyte immunophenotypes in persons infected with Treponema pallidum [J]. Clin DiagnLab Irnmunol,1994, 1(1): 121-124.
  • 5[2]Fitzgerald TJ. The Th1/Th2-1ike switch in syphilitic infection: is it detrimental?[J]. Infect Immun, 1992, 60(9): 3475-3479.
  • 6[3]Van Voorhis WC, Barrett LK, Koelle DM, et al. Primary and secondary syphilis lesions contain mRNA for Th1 cytokines[J]. J Infect Dis, 1996, 173(2): 491-495.
  • 7Keystone E, Wherry J, Grint P. IL - 10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am, 1998,24 ( 3 ) :629 - 639,.
  • 8Lusiak M, Podwinska J. lnterleukin 10 and its role in the regulation of the cell-mediated immune response in syphilis. Arch Immunol Ther Exp (Warsz) ,2001,49(6) :417 -421.
  • 9Akdis CA, Blaser K. Mechanisms of interleukin - 10 - mediated immune suppression. Immunology, 2001, 103(2) : 131 - 136.
  • 10Narula SK, Cutler D, Grint P. Immunomodulation of Crohng disease by interleukin -10. Agents Actions Suppl. 1998. 49:57 -65.

共引文献107

同被引文献74

  • 1杨文林,杨健,黄新宇.近10年梅毒血清固定患者临床分析[J].临床皮肤科杂志,2005,34(11):719-721. 被引量:89
  • 2包图雅,于娜沙,曾抗,李莉,方亮.梅毒血清固定患者细胞免疫功能研究[J].实用预防医学,2006,13(2):254-255. 被引量:29
  • 3黄捷,赖伟珍,韩红星,张瑛,陈庆芬.卡介菌多糖核酸对梅毒血清固定患者外周血T淋巴细胞亚群的影响[J].海南医学,2007,18(7):17-19. 被引量:13
  • 4Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006 [J]. MMWR Recomm Rep, 2006, 55(RR-11): 1-94.
  • 5Hook EW 3rd, Behets F, Van Damme K, et al. A phase III equivalence trial of azithromycin vs benzathine penicillin for treatment of early syphilis [J]. J Infect Dis, 2010, 201(11):1729-1735.
  • 6Lin LR, Zheng WH, Tong ML, et al. Further evaluation of the characteristics of Treponema pallidum-specific IgM antibody in syphilis serofast reaction patients [J]. Diagn Microbiol Infect Dis, 2011, 71(3):201-207.
  • 7Sefia AC, Wolff M, Martin DH, et al. Predictors of serological cure and Serofast State after treatment in HIV-negative persons with early syphilis [J]. Clin Infect Dis, 2011, 53(11): 1092-1099.
  • 8Li J, Wang LN, Zheng HY. Predictors of serological cure and serofast state after treatment in HIV-negative patients with early syphilis in China [J]. Sex Transm Infect, 2013, 89(1):69.
  • 9Tong ML, Lin LR, Liu GL, et al. Factors associated with serological cure and the serofast state of HIV-negative patients with primary, secondary, latent, and tertiary syphilis [J]. PLoS One, 2013, 8(7):e70102.
  • 10Chen XS, Yin YP, Wei WH, et al. High prevalence of azithromycin resistance to Treponema pallidum in geographically different areas in China [J]. Clin Microbiol Infect, 2013,19(10):975-979.

引证文献9

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部